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To evaluate MRI for neoadjuvant therapy response assessment in locally advanced rectal cancer (LARC) using dynamic contrast
enhanced-MRI (DCE-MRI) and diffusion weighted imaging (DWI), we have compared magnetic resonance volumetry based
on DCE-MRI (𝑉(DCE)) and on DWI (𝑉(DWI)) scans with conventional T2-weighted volumetry (𝑉(C)) in LARC patients
after neoadjuvant therapy. Twenty-nine patients with LARC underwent MR examination before and after neoadjuvant therapy.
A manual segmentation was performed on DCE-MR postcontrast images, on DWI (𝑏-value 800 s/mm2), and on conventional
T2-weighted images by two radiologists. DCE-MRI, DWI, and T2-weigthed volumetric changes before and after treatment
were evaluated. Nonparametric sample tests, interobserver agreement, and receiver operating characteristic curve (ROC) were
performed.Diagnostic performance linked toDCE-MRI volumetric changewas superior toT2-w andDW-MRI volumetric changes
performance (specificity 86%, sensitivity 93%, and accuracy 93%). Area Under ROC (AUC) of 𝑉(DCE) was greater than AUCs of
𝑉(C) and 𝑉(DWI) resulting in an increase of 15.6% and 11.1%, respectively. Interobserver agreement between two radiologists was
0.977, 0.864, and 0.756 for 𝑉(C), 𝑉(DCE), and 𝑉(DWI), respectively. 𝑉(DCE) seems to be a promising tool for therapy response
assessment in LARC. Further studies on large series of patients are needed to refine technique and evaluate its potential value.
1. Introduction
Rectal cancer is a frequent malignancy in both men and
women, accounting for 40.290 new cases in the USA in 2012
[1]. Despite the efforts done to introduce screening programs,
most patients are diagnosed in a locally advanced stage of
the disease (T3-T4, Nx, and Mx). Total mesorectal excision
(TME) combined with preoperative radiation therapy and
concurrent chemotherapy (pCRT) is the current standard
for locally advanced rectal cancer (LARC) [2]. TME is
associated with significant morbidity and functional compli-
cations, evolving conservative treatment strategies are being
developed for patients with early rectal cancer at diagnosis
and patients with significant/complete tumor regression after
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pCRT. A further conservative strategy has been to adopt
a “wait and see” policy, omitting surgery when a complete
clinical response is obtained after pCRT. This strategy has
the advantage of reducing morbidity and provides a “true”
organ-sparing approach, considering that sphincter preser-
vation without adequate function has questionable benefit.
CRT induces tumor downstaging and complete or partial
pathologic responses through vascular changes and cell death
[3]: a pathologic complete response (pCR) was verified in up
to 24% of patients. A pCR is known to be associated with a
favorable oncologic outcome, with regard to both recurrence
and survival [4, 5].MorphologicalMRI evaluation (mMRI) is
considered the best available tool for LARC staging, allowing
an accurate evaluation of the disease extent, up to and
beyond and over the mesorectal fascia, and of the lymph
node involvement [6]. However, there are some limitations
in depicting the changes after CRT through morphological
MRI alone. A favorable tumor response may not correspond
to an appreciable tumor size reduction. MR imaging, like
other morphologic imaging techniques (endorectal ultra-
sonography and computed tomography) is hampered by
interpretation difficulties in assessing the presence of residual
tumor within areas of radiation-induced fibrosis [6]. Studies
are therefore focusing on the potential added benefit of func-
tional and/or quantitative methods of MR image evaluation.
Functional MRI visualizes underlying biological characteris-
tics of tumors, adding a new dimension to the morphological
information from conventional MRI. The combination of
objective MRI biomarkers with detailed morphological MRI
makes MRI a potentially powerful response measurement
tool that provides comprehensive information on tumor
heterogeneity and changes in heterogeneity as a result of
treatment. Dynamic contrast-enhanced MRI (DCE-MRI)
has proven useful in detecting residual tumor after CRT [7].
Previous studies have been investigated functional parame-
ters derived by DCE-MRI dataset for noninvasive response
assessment in various malignancies, including rectal cancer
[8, 9]. Moreover, in various oncology fields, researchers have
recently suggested that diffusion-weighted imaging (DWI)
can potentially be used to identify biomarkers of treatment
response [3]. These assertions are based on the fact that DWI
could provide individual tumor apparent diffusion coefficient
(ADC) increase rates during the course of CRT, which could
reflect biological tumor changes.
DCE and DW MR imaging after CRT were shown to be
more valuable than morphologic MR imaging to recognize
pathological response from residual tumor, because on DCE
and DW images, viable tumor remnants are more easily rec-
ognized, as they appear hyperintense compared with the low
signal intensity (SI) of the surrounding non neoplastic tissue.
Hence, it can be hypothesized that volumetry of the tumor
that is based on SI characteristics on DCE or DW images
may be more accurate than conventional MR volumetry to
distinguish between complete and noncomplete responders.
With this study, we aim to determine the diagnostic
performance of DCE and DW imaging for the assessment
of a pathological response after CRT in patients with LARC
by means of volumetric SI measurements (𝑉(DCE) and
𝑉(DWI), resp.) and to compare the performance of DCE and
DW imaging with volumetry on conventional T2-weighted
MR images.
2. Materials and Methods
2.1. Patient Selection. Twenty-nine consecutive patients with
a median age of 62 years (range 29–76 years) were enrolled in
this prospective study, from March 2010 to November 2013.
All patients had a biopsy-proven rectal adenocarcinoma.
Endorectal ultrasonography, MRI of the liver and pelvis, CT
of the abdomen and pelvis, and chest X-ray were used as
staging procedures. Inclusion criteria were patients with clin-
ical T4, nodal involvement, or T3 N0 with a tumor location
of ≤5 cm from the anal verge, or a circumferential resection
margin of ≤5mm, defined by MRI. Exclusion criteria were
inability to give informed consent, previous rectal surgery,
and contraindications to MRI or to MR contrast media. All
patients were enrolled within the phase I-II prospective trial
described in [10] which was approved by the Independent
Ethical Committee of our institution. They all gave written
informed consent to participate in the trial.
2.2. Neoadjuvant Therapy. External radiation therapy was
performed using a 3-field technique (one posteroanterior and
two lateral fields). Standard fractions of 1.8 Gy/day to the
reference point were given, 5 times a week up to a total dose of
45Gy. All patients received biweekly bevacizumab at 5mg/kg
plus three biweekly cycles of oxaliplatin at 100mg/m2 and
raltitrexed at 2.5mg/m2, on day 1, and levo-folinic acid at
250mg/m2, and 5-Fluorouracil at 800mg/m2 on day 2 [2, 10].
2.3. MRI Data Acquisitions. All patients underwent DCE-
MRI examination before and after pCRT (90 days on average,
range 86–94 days between the twoMRI evaluations). Imaging
was performed with a 1.5 T scanner (Magnetom Symphony,
Siemens Medical System, Erlangen, Germany) equipped
with a phased-array body coil. Patients were placed in a
supine, head-first position. Mild rectal lumen distension was
achieved with 60–90mL of nondiluted ferumoxil (Lumirem,
Guerbet, RoissyCdGCedex, France) suspension introduced
per rectum [11]. Precontrast coronal T1w 2D turbo spin-echo
images and sagittal and axial T2w 2D turbo spin-echo images
of the pelvis were obtained. After that, axial DWIs were
acquired (spin-echo diffusion-weighted echo-planar imaging
[SE-DW-EPI]) at three 𝑏-values of 0, 400, and 800 sec/mm2.
Subsequently, axial, dynamic, contrast-enhanced T1w,
FLASH 3D gradient-echo images were acquired.We obtained
one sequence before and ten sequences, without any delay,
after IV injection of 2mL/kg of a positive, gadolinium-based
paramagnetic contrast medium (Gd-DOTA, Dotarem,
Guerbet, RoissyCdGCedex, France). The contrast medium
was injected using Spectris Solaris EP MR (MEDRAD Inc.,
Indianola, PA), with a flow rate of 2mL/s, followed by a 10
mL saline flush at the same rate. Temporal resolution was
0.58 minutes, corresponding to 35 seconds (as reported
in Table 1). Total acquisition time for precontrast and ten
postcontrast sequences was 6.4 minutes. Then, sagittal, axial,
and coronal postcontrast T1w 2D turbo spin-echo images,
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Table 1: Pulse sequence parameters on MR studies.
Sequence Orientation TR/TE/FA (ms/ms/deg.) AT (min) FOV (mm ×mm) Acquisition matrix ST/Gap (mm/mm) TF
T1w 2D TSE Coronal 499/13/150 2.36 450 × 450 256 × 230 3/0 3
T2w 2D TSE Sagittal 4820/98/150 4.17 260 × 236 256 × 139 3/0 13
T2w 2D TSE Axial 3970/98/150 3.48 270 × 236 256 × 157 3/0 13
SE-DW-EPI Axial 2700/83 6.37 136 × 160 160 × 102 4/0 /
T1w FLASH 3D Axial 9.8/4.76/25 0.58 330 × 247 256 × 192 3/0 /
T1w FLASH 3D Axial 9.8/4.76/25 0.58 × 10 330 × 247 256 × 192 3/0 /
T1w 2D TSE Sagittal 538/13/150 2.35 250 × 250 256 × 230 3/0 5
T1w 2D TSE Coronal 538/13/150 2.52 250 × 250 256 × 230 3/0 5
T1w 2D TSE Axial 450/12/150 2.31 270 × 236 256 × 202 3/0 5
Note: TR = repetition time, TE = echo time, FOV = field of view, FA = flip angle, ST = slice thickness, TF = turbo factor, and AT = acquisition time.
with and without fat saturation were obtained (Table 1). The
axial images were acquired without any angulation. Axial
T1-w pre- and postcontrast sequences were acquired at the
same position as the T2-w sequence. MRI total acquisition
time was around 40 minutes. Patients did not receive bowel
preparation, antispasmodic medication, or rectal distention
before any of the MR examinations.
2.4. Image Data Analysis. The MR images were evaluated
on a picture archiving and communication system and were
independently analyzed by two radiologists with years of
specific expertise reading pelvic MR images. The observers
were blinded to each other’s results, the clinical patient data,
and pathology reports.The readers calculated tumor volumes
by manually tracing the tumor boundaries slice by slice on
DCE-MRI derived images obtained subtracting the basal and
the 5th post-contrastographic series (𝑉(DCE)), on diffusion
weighted image a 𝑏-value of 800 s/mm2 (𝑉(DWI)) and on
conventional T2-weighted images (𝑉(C)).
Whole-tumor volume was then calculated considering
the total number of pixel (slice by slice) and multiplying this
by pixel size in mm2. On the T2-weighted images, tumor
was defined as areas of isointense signal as compared with
the relatively lower hypointense signal of the normal adjacent
muscular rectal wall. On post-CRT T2-weighted MR images,
areas of markedly low SI at the location of the primary tumor
bedwere interpreted as fibrosis. As the risk for residual tumor
in these fibrotic areas is known to be ±50%, they were also
included in the volumetric measurements [12]. On DCE-
MRI data sets, measurements were performed on subtraction
images considering basal signal and 5th postcontrastographic
series. Area of hyper-intense signal compared with normal
bowel wall or background of lower SI tissue, were considered
as tumor. On theDW images, measurements were performed
on high 𝑏 value (800 sec/mm2) images and were based on a
visual analysis. To avoid errors due to T2 shine effect only
areas with high SI on high-𝑏 value images and low SI on
ADC maps, when compared with the normal bowel wall or
background of lower SI tissue on high-𝑏 value images, were
considered tumor.
For each data sets (DCE, DWI, and T2-weigthed), the
readers determined (a) pre-CRT tumor volume; (b) post-CRT
tumor volume (TV); and (c) the tumor volume reduction
ratio (Δ volume), which was calculated as follows: (TVpre −
TVpost) × 100/TVpre, where TVpre is pre-CRT tumor volume
and TVpost is post-CRT tumor volume.
2.5. Surgical Approach and Evaluation of Pathologic Response.
All patients underwent total mesorectal excision after com-
pleting pCRT. An anterior resection or an abdominoperineal
resection was performed on the basis of the results of post-
CRT restaging. The surgical specimens containing the tumor
were processed and evaluated by a single pathologist whowas
not aware of the clinical and MRI findings. Specimens were
examined according to the Sixth American Joint Committee
on Cancer TNM staging system. The tumor regression grade
(TRG) was evaluated according to the method of Mandard
et al. [13, 14]. TRG 1 means a complete response with absence
of residual cancer and fibrosis extending through the wall.
TRG 2 is the presence of residual cancer cells scattered
through the fibrosis. TRG 3 corresponds to the presence of
fibrosis and tumor cells, with predominancy of fibrosis. TRG
4 indicates as fibrosis and tumor cells, with predominancy
of tumor cells. TRG 5 is the absence of regressive changes.
Patients with a TRG 1 or 2 score were considered as respon-
ders, whereas the remaining patients (TRG 3, 4, or 5) were
classified as not responders [9].
2.6. Statistical Analysis. Tumor volume percentage changes
of the responder and nonresponder groups were analyzed
using the Mann-Whitney test. A Wilcoxon signed-rank test
was used to compare pre- and post-CRT volumes. Receiver
Operating Characteristic (ROC) curves were also used to
compare the diagnostic performance of 𝑉(DCE), 𝑉(DWI)
and 𝑉(C) reduction rates after pCRT. Area Under ROC
Curve (AUC) were calculated [15] and optimal thresholds
were obtainedmaximizing the Youden index [16]. Sensitivity,
specificity, positive predictive value and negative predictive
value were performed considering optimal cut-off values.
Fischer exact tests were used to investigate if results were
statistically significant. Interobserver agreement was also
obtained using interobserver correlation coefficient (ICC) for
continuous variables (0–0.20, poor agreement; 0.21–0.40, fair
agreement; 0.41–0.60, moderate agreement; 0.61–0.80, good
agreement; and 0.81–1.00, excellent agreement).
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A 𝑝 value < 0.05 was considered significant for all tests.
All analyses were performed using Statistics Toolbox of
Matlab R2007a (The Math-Works Inc., Natick, MA).
3. Results
Histopathologic analysis of the surgical specimen yielded the
following findings: 5 patients had T0, 6 had T1, 14 had T2,
3 had T3, and 1 had T4 tumor. Five patients had TRG 1, 9
patients had TRG 2, 7 patients had TRG 3, and 8 patients had
TRG 4.
Table 2 shows patient characteristics and volume changes
assessed by the three volumetric methods: T2-w volumetric
change, DCE-MRI volumetric change and DW-MRI volu-
metric change. Table 3 shows median and standard deviation
values of volumes assessed by tree volumetric approaches
before and after treatment. Wilcoxon’s test findings reported
significant decreases in volumetric measures, between pre-
and posttreatment, assessed with all methods (Table 3):𝑉(C)
median value decreased from 36.9 cm3 to 16.7 cm3; 𝑉(DCE)
median value decreased from 30.9 cm3 to 16.5 cm3; 𝑉(DWI)
median value decreased from 14.59 cm3 to 6.0 cm3 (𝑝 < 0.01).
Statistically significant differences between responders
and not responders, in the volumetric percentage changes
were obtained by Mann-Whitney test for all volumetric
approaches (Table 3) and these were visualized in boxplots
(Figure 1). Table 4 reports the performance of three volumet-
ric methods in terms of sensitivity, specificity, and area under
ROC. Optimal cut-off values were also reported. The results
are statistically significant (Fisher test 𝑝 < 0.01).
According to TRG, DCE-MRI volume estimations
change after pCRT showed best results in terms of specificity,
sensitivity, and accuracy, respectively, of 86%, 93%, and 93%.
𝑉(C) showed a significant correlation between response
and TRG with a sensitivity, a specificity and an accuracy,
respectively, of 86%, 73%, and 79% (37% cut-off, AUC
0.76), and 𝑉(DWI) showed a sensitivity, a specificity and an
accuracy, respectively, of 64%, 94%, and 76% (39% cut-off,
AUC 0.81). Figure 2 shows ROCs for three volumetric
approaches. AUC of 𝑉(DCE) change is superior of AUCs of
𝑉(C) change and 𝑉(DWI) change resulting an increase of
15.6% and of 11.1%, respectively.
Interobserver agreement was 0.977 (95% confidence
interval (CI) 0.954–0.989), 0.864 (95% CI 0.835–0.884), and
0.756 (95% CI 0.705–0.780) for𝑉(C),𝑉(DCE), and𝑉(DWI).
4. Discussion
4.1. Synopsis of New Findings. The focus of this study was
to clarify the association between manual tumor volume
estimations obtained by T2-weigthed imaging, DWI, DCE-
MRI images, and TRG to predict LARC response after pCRT.
This study shows that manual tumor volume estimation
using DCE-MRI can furnish better performance in terms
of sensitivity, specificity, and accuracy. To the best of our
knowledge, no prior studies have compared the performances
ofmanual tumor volumemeasurements onT2-weighted (T2-
w), DWI, and DCE-MRI images to predict LARC response
after pCRT.
Table 2: Patient characteristics with volumetric change for individ-
ual patient.
Patient
number Age pT pN TRG
𝑉(C)
change
[%]
𝑉(DCE)
change
[%]
𝑉(DWI)
change
[%]
1 74 2 0 4 37,10 33,28 38,86
2 50 1 0 2 70,76 91,34 61,08
3 75 1 0 3 −96,50 29,88 36,67
4 54 1 0 2 61,22 67,40 −5,60
5 50 2 0 2 77,65 35,07 81,40
6 58 0 0 1 52,36 46,52 7,69
7 57 1 0 3 53,18 −3,71 62,42
8 67 0 0 1 80,34 70,57 72,33
9 70 1 1 2 59,99 39,59 46,72
10 75 2 0 2 77,81 78,21 22,49
11 78 2 1 3 8,85 −38,50 1,51
12 68 2 0 3 20,20 27,42 18,58
13 48 0 0 1 92,84 86,56 92,89
14 44 2 1 3 2,37 21,72 3,00
15 59 4 0 4 94,93 8,51 24,50
16 60 1 0 2 −4,52 28,52 39,50
17 63 2 0 3 21,73 13,52 −86,38
18 58 2 0 4 35,39 −2,57 43,52
19 44 2 0 4 66,01 34,08 22,63
20 63 3 1 4 28,05 3,26 −77,05
21 69 2 1 2 48,51 44,32 64,58
22 76 2 1 2 42,17 68,19 25,73
23 72 0 0 1 85,58 79,34 84,50
24 61 2 0 4 14,12 −83,35 −45,41
25 64 3 1 4 −45,75 20,64 21,25
26 58 3 0 3 44,51 18,94 28,28
27 76 2 0 2 50,72 60,61 36,40
28 77 2 0 4 13,16 75,04 −16,52
29 57 0 1 1 −23,73 12,45 49,65
Note: pT = pathological T stage; pN = pathological N stage; 𝑉(C) = con-
ventional T2-weighted volumetry; 𝑉(DWI) = diffusion-weighted imaging
volumetry; 𝑉(DCE) = dynamic contrast enhanced volumetry.
4.2. Comparisons with Other Studies. Tumor volume has
been proven to be an important prognostic indicator for a
variety of tumors, although the extra workload necessary
to perform manual tumor volume measurements on MRI
images have limited its applications in clinical routine. The
goal to be achieved after pCRT for LARC is pathologic
complete response. The latter could be assessed using the
TRG, a pathological score widely considered as a potential
tool to guide therapy in patients with LARC being an
independent predictor of the likelihood of local recurrence,
distant metastasis, and overall and disease-free survival [5].
Many approaches using MRI have been investigated to
compare response after pCRT with TRG. The correlation
shown between MR tumor volume estimation on T2-w
images and the pCR has been the subject of many reports
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Table 3: Volume measures assessed by the three volumetric methods (𝑉(C), 𝑉(DCE), and 𝑉(DWI)).
Tool All (𝑛 = 29) Responders (𝑛 = 14) Nonresponders (𝑛 = 15) p value
𝑉(C)
Pre-CRT [cm3] 36.9 ± 34.4 30.6 ± 22.6 38.4 ± 26.6
Post-CRT [cm3] 16.7 ± 8.8 12.4 ± 6.9 20.6 ± 9.5
Volume change [%] 44.5 ± 43.0 60.6 ± 33.2 21.7 ± 46.6 <0.001∗
𝑉(DCE)
Pre-CRT [cm3] 30.9 ± 29.1 31.4 ± 23.7 33.9 ± 25.4
Post-CRT [cm3] 18.5 ± 8.1 11.1 ± 6.7 24.7 ± 10.8
Volume change [%] 33.3 ± 38.4 64.0 ± 23.7 19.0 ± 36.9 <0.001∗
𝑉(DWI)
Pre-CRT [cm3] 14.6 ± 12.6 12.5 ± 10.1 15.8 ± 9.3
Post-CRT [cm3] 9.0 ± 5.1 6.4 ± 4.4 7.9 ± 5.5
Volume change [%] 28.3 ± 43.1 48.2 ± 30.0 21.2 ± 44.0 <0.001∗
Note: results are expressed as median value ± standard deviation.
∗Wilcoxon signed-rank test.
CRT, chemoradiation therapy; 𝑉(C), conventional T2-weighted volumetry; 𝑉(DWI), diffusion-weighted imaging volumetry; 𝑉(DCE), dynamic contrast
enhanced volumetry.
Table 4: Performance of volumetric approaches (𝑉(C), 𝑉(DCE), and 𝑉(DWI)).
Sensitivity [%] Specificity [%] Accuracy [%] Cut-off [%] AUC
𝑉(C) change 0.86 0.73 0.79 37.4 0.76
𝑉(DCE) change 0.86 0.93 0.93 34.2 0.90
𝑉(DWI) change 0.64 0.94 0.76 39.1 0.81
Note: 𝑉(C), conventional T2-weighted volumetry; 𝑉(DWI), diffusion-weighted imaging volumetry; 𝑉(DCE), dynamic contrast enhanced volumetry; AUC,
area under ROC.
[17–19], even if conflicting results were reported: Kang et al.
[20] showed a significant association with pCR for patients
with a tumor volume reduction rate of more than 75%,
whilst Kim et al. [21] observed no significant difference
between patient with a pCR and those with residual disease.
DW-MRI is an alternative technique potentially able to
overcome part of 𝑉(C) limits, being capable of showing
viable neoplastic tissue due to its reliability in detecting the
restricted proton diffusion in hypercellular tissues with high
nucleocytoplasmic ratio. According to some authors, the vol-
ume measurements obtained on post-CRT DW MR images
were significantly more accurate than those obtained on
post-CRT T2-w MR images to assess pathological complete
response [22–25]. DCE-MRI is another technique that can
provide functional information on tumor viability deriving
tumoral neoangiogenic changes linked to contrast medium
kinetics. Many authors described its potential advantages in
predict response to therapy in different tumors [5–7], where
neoformed tumor capillaries, being leaky, can determine
a rapid gadolinium uptake, an early wash-out and overall
shorter first pass, especially if compared with healthy tissues.
Moreover, this kinetic behavior of contrast agent in DCE-
MRI has been observed as correlated with some biomarkers
expressed by highly vascularized tumoral tissues, such as
the vascular endothelial growth factor expression and the
microvessel density [7–9, 26]. Volumetric measure could
be utilized in association with functional quantitative MRI
parameters to increase their accuracy for tumor response
therapy assessment. In fact, a recent study of Bajpai et al.
[27] reported that apparent diffusion coefficient obtained on
DW-MRI did not correlate with necrosis after chemotherapy
in osteosarcoma but on adjusting for volume (apparent
diffusion coefficient per unit volume); significant correlation
was found and this appears to be a sensitive substitute for
response evaluation in osteosarcoma. Future investigations
could be done using these recent findings.
However, few authors have proposed a tumor volume
estimation based on DCE-MRI images, using a manual or
an automatic segmentation, mainly focusing their works on
breast cancer [27, 28].Moreover, to the best of our knowledge,
no study has investigated the association between these
volumes measured by DCE-MRI and TRG in LARC.
4.3. Study Limitations. 𝑉(C) showed a significant correlation
between response and TRG with a sensitivity, a specificity
and an accuracy, respectively, of 86%, 73%, and 79% (37%
cut-off, AUC 0.76). Despite the excellent agreement between
observers (0.977), understaging was present in 5 patients
in which were assessed a decrease in volume >38% and a
TRG of 3 or 4, confirming that T2-w volume assessment
alone is not sufficiently accurate, being not able to identify
between the persistence of viable tissue and the peritumoral
fibrosis present after radiation therapy. Moreover, according
to observers, was difficult to decide which fibrotic areas,
remaining suspicious for tumor on T2-w images, should be
included in the volumemeasurements and which should not.
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Figure 1: Boxplots of three volumetric approaches: (a) shows𝑉(C) boxplot, (b) shows𝑉(DCE) boxplot, and (c) shows𝑉(DWI) boxplot.The
middle line is the median value. The inferior and superior extremes of the box correspond to the first and third quartiles, respectively. The
whiskers lines correspond to values within 1.5 times the interquartile range from the ends of the box. Outliner data beyond the ends of the
whiskers are displayed with a + sign.
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Figure 2: ROCs of three volumetric approaches (𝑉(C), 𝑉(DCE),
and 𝑉(DWI)).
𝑉(DWI) showed a sensitivity, a specificity, and an accuracy,
respectively, of 64%, 94%, and 76% (39% cut-off, AUC 0.81)
confirming the ability of 𝑉(DWI) in reducing the under-
staging observed with 𝑉(C) estimations. The agreement
between observers was good (0.756) and both observers
during segmentation easily and quickly recognized high-
SI areas of “viable tumor” thus avoiding the inclusion of
fibrotic areas that, due to their poor water content coupled
with lower nucleocytoplasmic ratio, were not visible on
either high 𝑏-value images and ADC maps. However, the
low sensitivity of 64% obtained in our series reflects some
intrinsic limits of 𝑉(DWI) measurements: during evaluation
it is mandatory to remember that small bleedings or friable
haemorrhagic/necrotic tissues can impact negatively on DW
evaluations, causing field inhomogeneity due to susceptibility
artefacts that, causing “enlargement” and “distortion” of
“bright” areas on 𝑏-800 images, can make the tumor segmen-
tation not accurate; the low spatial resolution with relative
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“small voxels” obtained, despite the large Field of View (FOV)
used, can be a source of wide differences in estimated volumes
causing tumor overestimation on post-CRT scans. Moreover,
to reduce potential sources of false negative due to overes-
timation of residual tumor, a comparative evaluation with
ADCmaps ismandatory when areas of necrosis are identified
and can be wrongly included in tumor being recognised like
bright areas on images acquired with high 𝑏-values (≥𝑏-800)
due to the “T2 shine effect” [29].𝑉(DCE) showed best results
with a sensitivity, a specificity, and an accuracy, respectively,
of 86%, 93%, and 93% (34% cut-off, AUC 0.90) coupled with
an excellent agreement between observers (0.864). Under
staging, only in 1 patient was present that, although showing a
great decrease in volume >37% on pCRT scan (75%), showed
a TRG of 4.This false negative was probably due to the tumor
appearance, which wasmainly vegetant, with a great decrease
in volume on 𝑉(DCE) measurements particularly on lumen
side, whilst the persisting extramural viable tumor tissue
was more easily detectable on T2-w and DW scans (as large
spiculae in mesorectal fat-pad or high intensity areas on 𝑏-
800 images). Only 2 patientswere false positive: these patients
constituted the main limit of 𝑉(DCE) segmentation. The
choice of segmenting tumor on subtracted images obtained
after 140s from contrast agent administration leaded to an
inclusion of those areas in which inflammation phenomena
were prominent (areas characterized by a continuous rise
in SI followed by a stable intensity over the time) with
an intrinsic potential overestimation, mainly on after pCRT
scans. However, being 𝑉(DCE) focussed to identify “not
effective” neoadjuvant treatments a false positive could be
more tolerated than a false negative.
4.4. Clinical Applicability of the Study. Despite interesting
results in terms of overall performance of𝑉(DCE), currently,
standard methods for tumor volume assessment based on
manual delineation of volumes are time consuming. The
mean time required to perform a volume measurement
using multiple ROIs was approximately 10–15 minutes when
pre-and post-CRT scans were considered and experienced
radiologists employed, which is impractical.Therefore, semi-
automated segmentation is needed.
5. Conclusions
In literature comparative studies between DCE-MRI, DW-
MRI, and conventional MR volumetry are not present to
assess therapy response evaluation after pCRT in LARC. In
our series, manual segmentation of tumor volumes, made
on DCE-MRI subtracted images, showed the best results in
terms of sensitivity, specificity, and accuracy. When these
results are validated in a larger prospective study and semiau-
tomated software will be available they could be implemented
in routine practice.
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